Focus on Innuvair<sup>®</sup> Inhaler for Asthma
Keywords:
Innuvair®, asthma
Abstract
The long-term goals of asthma management are to achieve good symptom control, to maintain normal activity levels and to minimise future risk of exacerbations, fixed airflow limitation and side-effects of treatment.1 The 2017 Global Initiative for Asthma (GINA) guidelines recommend that treatment with regular daily low-dose inhaled corticosteroids (ICS) is highly effective in reducing asthma symptoms and in reducing the risk of asthma-related exacerbations.1 For patients with persistent symptoms and/or exacerbations despite low-dose ICS, the preferred step-up treatment (Step 3) is combination low-dose ICS/long-acting beta2-agonist (LABA) therapy.1
Section
Product Focus
By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the South African Academy of Family Physicians. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.
